WallStSmart

ResMed Inc (RMD)vsSanara Medtech Inc (SMTI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 5199% more annual revenue ($5.40B vs $101.88M). RMD leads profitability with a 27.5% profit margin vs -36.8%. RMD earns a higher WallStSmart Score of 70/100 (B).

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34

SMTI

Avoid

32

out of 100

Grade: F

Growth: 7.3Profit: 3.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Intrinsic value data unavailable for SMTI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

SMTI1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
21.5%8/10

Revenue surging 21.5% year-over-year

Areas to Watch

RMD0 concerns · Avg: 0/10

No major concerns identified

SMTI4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$163.88M3/10

Smaller company, higher risk/reward

Price/BookValuation
23.7x2/10

Trading at 23.7x book value

Return on EquityProfitability
-27.8%2/10

ROE of -27.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bull Case : SMTI

The strongest argument for SMTI centers on Revenue Growth. Revenue growth of 21.5% demonstrates continued momentum.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Bear Case : SMTI

The primary concerns for SMTI are EPS Growth, Market Cap, Price/Book.

Key Dynamics to Monitor

RMD profiles as a mature stock while SMTI is a growth play — different risk/reward profiles.

SMTI carries more volatility with a beta of 1.05 — expect wider price swings.

SMTI is growing revenue faster at 21.5% — sustainability is the question.

RMD generates stronger free cash flow (311M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 32/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Sanara Medtech Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Sanara MedTech Inc. develops, markets and distributes skin and wound care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company is headquartered in Fort Worth, Texas.

Want to dig deeper into these stocks?